AC
MDGL icon

Allstate Corporation’s Madrigal Pharmaceuticals MDGL Stock Holding History

Allstate Corporation’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$826K Sell
1,539
-698
-31% -$358K 0.01% 831
2026
Q1 		$1.17M Buy
+2,237
New +$1.07M 0.01% 749

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Allstate Corporation's MDGL Position: Q2 2026 in Review

Allstate Corporation reduced its Madrigal Pharmaceuticals (MDGL) stake by 31% in Q2 2026, selling an estimated $358K and leaving 1,539 shares worth $826K. The position accounts for 0.01% of the portfolio, ranked #831.

Allstate Corporation first reported a position in MDGL in Q1 2026 and has held it in 2 quarters since. The position peaked at $1.17M in Q1 2026. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Allstate Corporation held 1,539 shares of Madrigal Pharmaceuticals worth $826K as of Q2 2026.
  • Allstate Corporation sold 698 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $358K.
  • Madrigal Pharmaceuticals made up 0.01% of Allstate Corporation's portfolio in Q2 2026, its #831 holding.
  • Allstate Corporation first reported a position in Madrigal Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Allstate Corporation's Madrigal Pharmaceuticals position peaked at $1.17M in Q1 2026.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.